Nevertheless, receiving results of further hematological diagnostics would be of great interest for patients with mutations in JAK2 V617 with VAF > 2% to differentiate MPN from clonal hematopoiesis of indeterminate potential (CHIP) and in those with VAF between 1.0% and 1.9%. Here, JAK2 is linked to myeloproliferative neoplasm.